NICE yes for NSCLC diagnostic tests could impact Iressa and Tarceva
This article was originally published in Scrip
Executive Summary
New guidance from NICE, the health technology appraisal institute for England and Wales, recommending EGFR-tyrosine kinase mutation tests for routine use on the National Health Service could improve the treatment of non-small cell lung cancer treatment. It could also impact use of Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), the two EGFR-TK inhibitors recommended by NICE to treat NSCLC.
You may also be interested in...
Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
Will COVID-19 Drive The Decline Of International Reference Pricing?
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.
EU Orphan And Pediatric Proposals Insufficient, Says Industry
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.
Need a specific report? 1000+ reports available
Buy Reports